Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 145
Filter
1.
Sci Rep ; 12(1): 6764, 2022 Apr 26.
Article in English | MEDLINE | ID: mdl-35473944

ABSTRACT

We derive the Hamiltonian of a superconducting circuit that comprises a single-Josephson-junction flux qubit inductively coupled to an LC oscillator, and we compare the derived circuit Hamiltonian with the quantum Rabi Hamiltonian, which describes a two-level system coupled to a harmonic oscillator. We show that there is a simple, intuitive correspondence between the circuit Hamiltonian and the quantum Rabi Hamiltonian. While there is an overall shift of the entire spectrum, the energy level structure of the circuit Hamiltonian up to the seventh excited states can still be fitted well by the quantum Rabi Hamiltonian even in the case where the coupling strength is larger than the frequencies of the qubit and the oscillator, i.e., when the qubit-oscillator circuit is in the deep-strong-coupling regime. We also show that although the circuit Hamiltonian can be transformed via a unitary transformation to a Hamiltonian containing a capacitive coupling term, the resulting circuit Hamiltonian cannot be approximated by the variant of the quantum Rabi Hamiltonian that is obtained using an analogous procedure for mapping the circuit variables onto Pauli and harmonic oscillator operators, even for relatively weak coupling. This difference between the flux and charge gauges follows from the properties of the qubit Hamiltonian eigenstates.

2.
Phys Rev Lett ; 120(18): 183601, 2018 May 04.
Article in English | MEDLINE | ID: mdl-29775324

ABSTRACT

We report on experimentally measured light shifts of superconducting flux qubits deep-strongly coupled to LC oscillators, where the coupling constants are comparable to the qubit and oscillator resonance frequencies. By using two-tone spectroscopy, the energies of the six lowest levels of each circuit are determined. We find huge Lamb shifts that exceed 90% of the bare qubit frequencies and inversions of the qubits' ground and excited states when there are a finite number of photons in the oscillator. Our experimental results agree with theoretical predictions based on the quantum Rabi model.

3.
Oncogene ; 36(14): 2023-2029, 2017 04 06.
Article in English | MEDLINE | ID: mdl-27694896

ABSTRACT

Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34-43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.


Subject(s)
Carcinogenesis/genetics , Carcinogenesis/pathology , Carcinogenicity Tests/methods , Genetic Association Studies/methods , Oncogenes , Animals , Cell Line, Tumor , Female , Gene Expression Regulation, Neoplastic , Heterografts , Humans , Male , Mice , Mice, Nude , Neoplasms/genetics , Neoplasms/mortality , Neoplasms/pathology , Oligonucleotide Array Sequence Analysis , Phenotype
4.
J Phys Condens Matter ; 28(27): 275302, 2016 07 13.
Article in English | MEDLINE | ID: mdl-27214571

ABSTRACT

Optically detected magnetic resonance (ODMR) is a way to characterize the ensemble of NV-centers. Recently, a remarkably sharp dip was observed in the ODMR with a high-density ensemble of NV centers. The model (Zhu et al 2014 Nat. Commun. 5 3424) indicated that such a dip was due to the spin-1 properties of the NV- centers. Here, we present many more details of the analysis to show how this model can be applied to investigate the properties of the NV- centers. By using our model, we have reproduced the ODMR with and without applied external magnetic fields. Additionally, we investigate how the ODMR is affected by the typical parameters of the ensemble NV- centers such as strain distributions, inhomogeneous magnetic fields, and homogeneous broadening width. Our model provides a way to characterize the NV- center from the ODMR, which would be crucial to realize diamond-based quantum information processing.

5.
Oncogene ; 35(18): 2407-12, 2016 05 05.
Article in English | MEDLINE | ID: mdl-26257060

ABSTRACT

Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein α subunit (Gsα) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gsα. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, loss of acinar cells and fibrosis in the pancreas; however, no macroscopic tumorigenesis was apparent by 2 months of age. We then crossed Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice with LSL-Kras(G12D) mice, generating Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice. We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis. Within 5 weeks, Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice developed a cystic tumor consisting of marked dilated ducts lined with papillary dysplastic epithelia in the pancreas, which closely mimicked the human IPMN. Our data strongly suggest that activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis, which recapitulates IPMN. Our mouse model may serve as a unique in vivo platform to find biomarkers and effective drugs for diseases associated with GNAS mutations.


Subject(s)
Carcinogenesis/genetics , Carcinoma, Pancreatic Ductal/pathology , Chromogranins/genetics , GTP-Binding Protein alpha Subunits, Gs/genetics , Mutation , Pancreatic Neoplasms/pathology , Proto-Oncogene Proteins p21(ras)/genetics , Animals , Female , Humans , Male , Mice , Pancreatic Neoplasms/genetics
6.
J Phys Condens Matter ; 27(34): 345702, 2015 Sep 04.
Article in English | MEDLINE | ID: mdl-26252646

ABSTRACT

A hybrid system that combines the advantages of a superconductor flux qubit and an electron spin ensemble in diamond is one of the promising devices to realize quantum information processing. Exploring the properties of the superconductor diamond system is essential for the efficient use of this device. When we perform spectroscopy of this system, significant power broadening is observed. However, previous models to describe this system are known to be applicable only when the power broadening is negligible. Here, we construct a new approach to analyze this system with strong driving, and succeed in reproducing the spectrum with the power broadening. Our results provide an efficient way to analyze this hybrid system.

7.
Cell Death Dis ; 5: e1333, 2014 Jul 17.
Article in English | MEDLINE | ID: mdl-25032856

ABSTRACT

Glaucoma, one of the leading causes of irreversible blindness, is characterized by progressive degeneration of optic nerves and retinal ganglion cells (RGCs). In the mammalian retina, excitatory amino acid carrier 1 (EAAC1) is expressed in neural cells, including RGCs, and the loss of EAAC1 leads to RGC degeneration without elevated intraocular pressure (IOP). In the present study, we found that expressions of angiotensin II type 1 receptor (AT1-R) and Toll-like receptor 4 (TLR4) are increased in RGCs and retinal Müller glia in EAAC1-deficient (KO) mice. The orally active AT1-R antagonist candesartan suppressed TLR4 and lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) expressions in the EAAC1 KO mouse retina. Sequential in vivo retinal imaging and electrophysiological analysis revealed that treatment with candesartan was effective for RGC protection in EAAC1 KO mice without affecting IOP. In cultured Müller glia, candesartan suppressed LPS-induced iNOS production by inhibiting the TLR4-apoptosis signal-regulating kinase 1 pathway. These results suggest that the renin-angiotensin system is involved in the innate immune responses in both neural and glial cells, which accelerate neural cell death. Our findings raise intriguing possibilities for the management of glaucoma by utilizing widely prescribed drugs for the treatment of high blood pressure, in combination with conventional treatments to lower IOP.


Subject(s)
Glaucoma/metabolism , Renin-Angiotensin System , Retinal Ganglion Cells/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Animals , Cell Death , Disease Models, Animal , Excitatory Amino Acid Transporter 3/deficiency , Excitatory Amino Acid Transporter 3/genetics , Glaucoma/enzymology , Glaucoma/genetics , Humans , Mice , Mice, Knockout , Retina/enzymology , Retina/metabolism , Signal Transduction , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
8.
Cell Death Dis ; 5: e1341, 2014 Jul 17.
Article in English | MEDLINE | ID: mdl-25032864

ABSTRACT

Glaucoma is one of the leading causes of irreversible blindness that is characterized by progressive degeneration of optic nerves and retinal ganglion cells (RGCs). In the mammalian retina, excitatory amino-acid carrier 1 (EAAC1) is expressed in neural cells, including RGCs, and the loss of EAAC1 leads to RGC degeneration without elevated intraocular pressure (IOP). Brimonidine (BMD) is an α2-adrenergic receptor agonist and it is commonly used in a form of eye drops to lower IOP in glaucoma patients. Recent studies have suggested that BMD has direct protective effects on RGCs involving IOP-independent mechanisms, but it is still controversial. In the present study, we examined the effects of BMD in EAAC1-deficient (KO) mice, an animal model of normal tension glaucoma. BMD caused a small decrease in IOP, but sequential in vivo retinal imaging and electrophysiological analysis revealed that treatment with BMD was highly effective for RGC protection in EAAC1 KO mice. BMD suppressed the phosphorylation of the N-methyl-D-aspartate receptor 2B (NR2B) subunit in RGCs in EAAC1 KO mice. Furthermore, in cultured Müller glia, BMD stimulated the production of several neurotrophic factors that enhance RGC survival. These results suggest that, in addition to lowering IOP, BMD prevents glaucomatous retinal degeneration by stimulating multiple pathways including glia-neuron interactions.


Subject(s)
Glaucoma/drug therapy , Protective Agents/administration & dosage , Quinoxalines/administration & dosage , Retinal Degeneration/prevention & control , Retinal Ganglion Cells/drug effects , Animals , Brimonidine Tartrate , Excitatory Amino Acid Transporter 3/genetics , Excitatory Amino Acid Transporter 3/metabolism , Female , Glaucoma/genetics , Glaucoma/metabolism , Glaucoma/physiopathology , Humans , Male , Mice , Mice, Knockout , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/metabolism , Retinal Degeneration/genetics , Retinal Degeneration/metabolism , Retinal Degeneration/physiopathology
9.
Neuroscience ; 277: 174-83, 2014 Sep 26.
Article in English | MEDLINE | ID: mdl-25010399

ABSTRACT

Chronic sleep restriction (CSR) has various negative consequences on cognitive performance and health. Using a rat model of CSR that uses alternating cycles of 3h of sleep deprivation (using slowly rotating activity wheels) and 1h of sleep opportunity continuously for 4 days ('3/1' protocol), we previously observed not only homeostatic but also allostatic (adaptive) sleep responses to CSR. In particular, non-rapid eye movement sleep (NREMS) electroencephalogram (EEG) delta power, an index of sleep intensity, increased initially and then declined gradually during CSR, with no rebound during a 2-day recovery period. To study underlying mechanisms of these allostatic responses, we examined the levels of brain-derived neurotrophic factor (BDNF), which is known to regulate NREMS EEG delta activity, during the same CSR protocol. Mature BDNF protein levels were measured in the frontal cortex and basal forebrain, two brain regions involved in sleep and EEG regulation, and the hippocampus, using Western blot analysis. Adult male Wistar rats were housed in motorized activity wheels, and underwent the 3/1 CSR protocol for 27 h, for 99 h, or for 99 h followed by 24h of recovery. Additional rats were housed in either locked wheels (locked wheel controls [LWCs]) or unlocked wheels that rats could rotate freely (wheel-running controls [WRCs]). BDNF levels did not differ between WRC and LWC groups. BDNF levels were increased, compared to the control levels, in all three brain regions after 27 h, and were increased less strongly after 99 h, of CSR. After 24h of recovery, BDNF levels were at the control levels. This time course of BDNF levels parallels the previously reported changes in NREMS delta power during the same CSR protocol. Changes in BDNF protein levels in the cortex and basal forebrain may be part of the molecular mechanisms underlying allostatic sleep responses to CSR.


Subject(s)
Adaptation, Physiological/physiology , Basal Forebrain/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Frontal Lobe/metabolism , Hippocampus/metabolism , Sleep Deprivation/metabolism , Adrenal Glands/physiology , Animals , Blotting, Western , Body Weight , Chronic Disease , Male , Motor Activity/physiology , Organ Size , Random Allocation , Rats, Wistar
11.
Cell Death Differ ; 20(2): 270-80, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22976835

ABSTRACT

Optic nerve injury (ONI) induces retinal ganglion cell (RGC) death and optic nerve atrophy that lead to visual loss. Apoptosis signal-regulating kinase 1 (ASK1) is an evolutionarily conserved mitogen-activated protein kinase (MAPK) kinase kinase and has an important role in stress-induced RGC apoptosis. In this study, we found that ONI-induced p38 activation and RGC loss were suppressed in ASK1-deficient mice. Sequential in vivo retinal imaging revealed that post-ONI treatment with a p38 inhibitor into the eyeball was effective for RGC protection. ONI-induced monocyte chemotactic protein-1 production in RGCs and microglial accumulation around RGCs were suppressed in ASK1-deficient mice. In addition, the productions of tumor necrosis factor and inducible nitric oxide synthase in microglia were decreased when the ASK1-p38 pathway was blocked. These results suggest that ASK1 activation in both neural and glial cells is involved in neural cell death, and that pharmacological interruption of ASK1-p38 pathways could be beneficial in the treatment of ONI.


Subject(s)
Apoptosis , MAP Kinase Kinase Kinase 5/metabolism , Neurons/enzymology , Optic Nerve Injuries/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Animals , Cells, Cultured , Imidazoles/pharmacology , MAP Kinase Kinase Kinase 5/antagonists & inhibitors , MAP Kinase Kinase Kinase 5/genetics , Mice , Mice, Knockout , Nitric Oxide Synthase Type II/metabolism , Optic Nerve Injuries/pathology , Phosphorylation/drug effects , Pyridines/pharmacology , Retinal Ganglion Cells/cytology , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/metabolism , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
12.
Oncogene ; 32(1): 27-38, 2013 Jan 03.
Article in English | MEDLINE | ID: mdl-22349823

ABSTRACT

The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain. The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic. They display sensitivity to TK inhibitors, including gefitinib and erlotinib. In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants. In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant. The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity. The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant. Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation. The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands. In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop. Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity. Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-associated EGFR mutations.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , ErbB Receptors/genetics , Lung Neoplasms/drug therapy , Mutation , Quinazolines/therapeutic use , Carcinoma, Non-Small-Cell Lung/genetics , Drug Screening Assays, Antitumor , ErbB Receptors/chemistry , Gefitinib , Humans , Lung Neoplasms/genetics , Protein Conformation , Protein-Tyrosine Kinases/genetics
13.
Am J Physiol Regul Integr Comp Physiol ; 302(12): R1411-25, 2012 Jun 15.
Article in English | MEDLINE | ID: mdl-22492816

ABSTRACT

To study sleep responses to chronic sleep restriction (CSR) and time-of-day influences on these responses, we developed a rat model of CSR that takes into account the polyphasic sleep patterns in rats. Adult male rats underwent cycles of 3 h of sleep deprivation (SD) and 1 h of sleep opportunity (SO) continuously for 4 days, beginning at the onset of the 12-h light phase ("3/1" protocol). Electroencephalogram (EEG) and electromyogram (EMG) recordings were made before, during, and after CSR. During CSR, total sleep time was reduced by ∼60% from baseline levels. Both rapid eye movement sleep (REMS) and non-rapid eye movement sleep (NREMS) during SO periods increased initially relative to baseline and remained elevated for the rest of the CSR period. In contrast, NREMS EEG delta power (a measure of sleep intensity) increased initially, but then declined gradually, in parallel with increases in high-frequency power in the NREMS EEG. The amplitude of daily rhythms in NREMS and REMS amounts was maintained during SO periods, whereas that of NREMS delta power was reduced. Compensatory responses during the 2-day post-CSR recovery period were either modest or negative and gated by time of day. NREMS, REMS, and EEG delta power lost during CSR were not recovered by the end of the second recovery day. Thus the "3/1" CSR protocol triggered both homeostatic responses (increased sleep amounts and intensity during SOs) and allostatic responses (gradual decline in sleep intensity during SOs and muted or negative post-CSR sleep recovery), and both responses were modulated by time of day.


Subject(s)
Allostasis/physiology , Sleep Deprivation/physiopathology , Sleep/physiology , Animals , Electroencephalography , Electromyography , Homeostasis/physiology , Male , Rats , Rats, Wistar , Wakefulness/physiology
14.
Oncogene ; 31(26): 3190-201, 2012 Jun 28.
Article in English | MEDLINE | ID: mdl-22037216

ABSTRACT

Epithelial-mesenchymal transition (EMT) is a crucial event in wound healing, tissue repair and cancer progression in adult tissues. We have recently shown that transforming growth factor (TGF)-ß-induced EMT involves isoform switching of fibroblast growth factor receptors by alternative splicing. We performed a microarray-based analysis at single exon level to elucidate changes in splicing variants generated during TGF-ß-induced EMT, and found that TGF-ß induces broad alteration of splicing patterns by downregulating epithelial splicing regulatory proteins (ESRPs). This was achieved by TGF-ß-mediated upregulation of δEF1 family proteins, δEF1 and SIP1. δEF1 and SIP1 each remarkably repressed ESRP2 transcription through binding to the ESRP2 promoter in NMuMG cells. Silencing of both δEF1 and SIP1, but not either alone, abolished the TGF-ß-induced ESRP repression. The expression profiles of ESRPs were inversely related to those of δEF1 and SIP in human breast cancer cell lines and primary tumor specimens. Further, overexpression of ESRPs in TGF-ß-treated cells resulted in restoration of the epithelial splicing profiles as well as attenuation of certain phenotypes of EMT. Therefore, δEF1 family proteins repress the expression of ESRPs to regulate alternative splicing during TGF-ß-induced EMT and the progression of breast cancers.


Subject(s)
Down-Regulation/drug effects , Epithelial-Mesenchymal Transition/drug effects , Homeodomain Proteins/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Transcription Factors/metabolism , Transforming Growth Factor beta/pharmacology , Alternative Splicing/drug effects , Animals , Breast Neoplasms/pathology , Cadherins/genetics , Cell Line, Tumor , Disease Progression , Down-Regulation/genetics , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/genetics , Homeodomain Proteins/genetics , Humans , Mice , Nerve Tissue Proteins/genetics , Phenotype , Protein Isoforms/genetics , Receptors, Fibroblast Growth Factor/genetics , Transcription Factors/genetics , Zinc Finger E-box-Binding Homeobox 1
15.
Neuroscience ; 170(4): 1140-52, 2010 Nov 10.
Article in English | MEDLINE | ID: mdl-20727388

ABSTRACT

Long-term (>48 h) sleep deprivation (SD) reduces adult rat hippocampal cell proliferation and neurogenesis, yet reported effects of short-term (<24 h) SD are inconsistent. We systematically assessed the effects of various durations of SD on adult rat hippocampal cell proliferation. Rats were sleep-deprived for 6, 12, 24, 36 or 48 h and injected with 5-bromo-2'-deoxyuridine (BrdU) 2 h before the end of SD. Immunolabeling for BrdU in the hippocampal subgranular zone increased significantly after 12 h SD but tended to decrease after 48 h SD relative to respective Controls. Surprisingly, SD did not alter immunolabeling for Ki67 protein (Ki67) or proliferating cell nuclear antigen (PCNA), two intrinsic cell proliferation markers. SD did not affect BrdU or Ki67 labeling in the subventricular zone, nor did it affect serum corticosterone levels. Because immunoreactivity for Ki67 and PCNA can identify cells in all phases of the ∼25 h cell cycle in adult rat hippocampus, whereas BrdU labels only cells in S-phase (∼9.5 h), this discrepancy suggests that 12 h SD might have affected cell cycle dynamics. A separate group of rats were injected with BrdU 10 h before the end of 12 h SD, which would allow some time for labeled cells to divide; the results were consistent with an acceleration of the timing of hippocampal progenitor cell division during 12 h SD. These results suggest that short-term (12 h) SD transiently produces more hippocampal progenitor cells via cell cycle acceleration, and confirm the importance of using multiple cell cycle markers or BrdU injection paradigms to assess potential changes in cell proliferation.


Subject(s)
Hippocampus/cytology , Sleep Deprivation , Animals , Biomarkers/metabolism , Bromodeoxyuridine , Cell Count , Cell Proliferation , Hippocampus/metabolism , Immunohistochemistry , Indicators and Reagents , Ki-67 Antigen/metabolism , Male , Proliferating Cell Nuclear Antigen/metabolism , Rats , Rats, Sprague-Dawley
17.
Am J Physiol Regul Integr Comp Physiol ; 295(4): R1328-40, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18753261

ABSTRACT

To understand how female sex hormones influence homeostatic mechanisms of sleep, we studied the effects of estradiol (E(2)) replacement on c-Fos immunoreactivity in sleep/wake-regulatory brain areas after sleep deprivation (SD) in ovariectomized rats. Adult rats were ovariectomized and implanted subcutaneously with capsules containing 17beta-E(2) (10.5 microg; to mimic diestrous E(2) levels) or oil. After 2 wk, animals with E(2) capsules received a single subcutaneous injection of 17beta-E(2) (10 microg/kg; to achieve proestrous E(2) levels) or oil; control animals with oil capsules received an oil injection. Twenty-four hours later, animals were either left undisturbed or sleep deprived by "gentle handling" for 6 h during the early light phase, and killed. E(2) treatment increased serum E(2) levels and uterus weights dose dependently, while attenuating body weight gain. Regardless of hormonal conditions, SD increased c-Fos immunoreactivity in all four arousal-promoting areas and four limbic and neuroendocrine nuclei studied, whereas it decreased c-Fos labeling in the sleep-promoting ventrolateral preoptic nucleus (VLPO). Low and high E(2) treatments enhanced the SD-induced c-Fos immunoreactivity in the laterodorsal subnucleus of the bed nucleus of stria terminalis and the tuberomammillary nucleus, and in orexin-containing hypothalamic neurons, with no effect on the basal forebrain and locus coeruleus. The high E(2) treatment decreased c-Fos labeling in the VLPO under nondeprived conditions. These results indicate that E(2) replacement modulates SD-induced or spontaneous c-Fos expression in sleep/wake-regulatory and limbic forebrain nuclei. These modulatory effects of E(2) replacement on neuronal activity may be, in part, responsible for E(2)'s influence on sleep/wake behavior.


Subject(s)
Estradiol/pharmacology , Estrogen Replacement Therapy , Ovariectomy , Proto-Oncogene Proteins c-fos/metabolism , Sleep Deprivation/physiopathology , Animals , Body Weight/drug effects , Estradiol/blood , Estradiol/therapeutic use , Female , Hypothalamic Area, Lateral/cytology , Hypothalamic Area, Lateral/drug effects , Hypothalamic Area, Lateral/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Neurons/cytology , Neurons/drug effects , Neurons/metabolism , Neuropeptides/metabolism , Orexins , Organ Size/drug effects , Preoptic Area/cytology , Preoptic Area/metabolism , Prosencephalon/cytology , Prosencephalon/drug effects , Prosencephalon/metabolism , Rats , Rats, Wistar , Septal Nuclei/cytology , Septal Nuclei/drug effects , Septal Nuclei/metabolism , Sleep/drug effects , Sleep/physiology , Uterus/anatomy & histology , Uterus/drug effects
18.
Oncogene ; 27(3): 274-84, 2008 Jan 10.
Article in English | MEDLINE | ID: mdl-17621269

ABSTRACT

The Wnt signaling pathway is essential for embryonic development and carcinogenesis. Upon Wnt stimulation, beta-catenin is stabilized and associates with T-cell factor or lymphoid enhancing factor, thereby activating transcription of target genes. In the absence of Wnt stimulation, the level of beta-catenin is reduced via glycogen synthase kinase (GSK)-3beta-mediated phosphorylation and subsequent proteasome-dependent degradation. Here, we report the identification of Ajuba as a negative regulator of the Wnt signaling pathway. Ajuba is a member of LIM domain-containing proteins that contribute to cell fate determination and regulate cell proliferation and differentiation. We found that enforced expression of Ajuba destabilized beta-catenin and suppressed target gene expression. Ajuba promoted GSK-3beta-mediated phosphorylation of beta-catenin by reinforcing the association between beta-catenin and GSK-3beta. Furthermore, Wnt stimulation induced both accumulation of beta-catenin and destabilization of Ajuba. Our findings suggest that Ajuba is important for regulation of the Wnt signaling pathway.


Subject(s)
Glycogen Synthase Kinase 3/metabolism , Homeodomain Proteins/metabolism , Wnt Proteins/metabolism , beta Catenin/metabolism , Cell Line, Tumor , Glycogen Synthase Kinase 3 beta , Homeodomain Proteins/analysis , Homeodomain Proteins/genetics , Humans , LIM Domain Proteins , Phosphorylation , Protein Interaction Mapping , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Signal Transduction , Transcription, Genetic , Transcriptional Activation , Wnt Proteins/antagonists & inhibitors , beta Catenin/analysis
19.
Neuroscience ; 149(1): 232-41, 2007 Oct 12.
Article in English | MEDLINE | ID: mdl-17850979

ABSTRACT

Sensory stimulation and electrical stimulation of sensory pathways evoke an increase in acetylcholine release from the corresponding cortical areas. The pathways by which such sensory information reaches the cholinergic neurons of the basal forebrain that are responsible for this release are unclear, but have been hypothesized to pass through the prefrontal cortex (PFC). This hypothesis was tested in urethane-anesthetized rats using microdialysis to collect acetylcholine from somatosensory, visual, or auditory cortex, before and after the PFC was inactivated by local microdialysis delivery of the GABA-A receptor agonist muscimol (0.2% for 10 min at 2 microl/min). Before PFC inactivation, peripheral sensory stimulation and ventral posterolateral thalamic stimulation evoked 60 and 105% increases, respectively, in acetylcholine release from somatosensory cortex. Stimulation of the lateral geniculate nucleus evoked a 57% increase in acetylcholine release from visual cortex and stimulation of the medial geniculate nucleus evoked a 72% increase from auditory cortex. Muscimol delivery to the PFC completely abolished each of these evoked increases (overall mean change from baseline = -7%). In addition, the spontaneous level of acetylcholine release in somatosensory, visual, and auditory cortices was reduced by 15-59% following PFC inactivation, suggesting that PFC activity has a tonic facilitatory influence on the basal forebrain cholinergic neurons. These experiments demonstrate that the PFC is necessary for sensory pathway evoked cortical ACh release and strongly support the proposed sensory cortex-to-PFC-to-basal forebrain circuit for each of these modalities.


Subject(s)
Acetylcholine/metabolism , Afferent Pathways/physiology , Auditory Cortex/metabolism , Prefrontal Cortex/physiology , Somatosensory Cortex/metabolism , Visual Cortex/metabolism , Afferent Pathways/drug effects , Afferent Pathways/radiation effects , Analysis of Variance , Animals , GABA Agonists/pharmacology , Male , Microdialysis/methods , Muscimol/pharmacology , Prefrontal Cortex/drug effects , Prefrontal Cortex/injuries , Rats , Rats, Wistar
20.
Phys Rev Lett ; 98(26): 260407, 2007 Jun 29.
Article in English | MEDLINE | ID: mdl-17678075

ABSTRACT

Rubidium-87 atoms are trapped in an Ioffe-Pritchard potential generated with a persistent supercurrent that flows in a loop circuit patterned on a sapphire surface. The superconducting circuit is a closed loop made of a 100 microm wide molecular-beam epitaxy-grown MgB2 stripe carrying a supercurrent of 2.5 A. To control the supercurrent in the stripe, an on-chip thermal switch operated by a focused argon-ion laser is developed. The switch operates as an on/off switch of the supercurrent or as a device to set the current to a specific value with the aid of an external magnetic field. The current can be set even without an external source if the change is in the decreasing direction.

SELECTION OF CITATIONS
SEARCH DETAIL
...